Stay updated with breaking news from Eric Duncavage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
GatewaySeq, a genetic test that identifies cancer mutations in solid tumors and that was developed by researchers at Washington University School of Medicine in St. Louis, has been approved for reimbursement by the Centers for Medicare & Medicaid Services.
A new test for two blood cancers — developed by a team at Washington University School of Medicine in St. Louis — is the first whole-genome sequencing test for cancer to be approved for reimbursement by the Centers for Medicare & Medicaid Service
A new test for two blood cancers – developed by a team at Washington University School of Medicine in St. Louis – is the first whole-genome sequencing test for cancer to be approved for reimbursement by the Centers for Medicare & Medicaid Services.
/PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of Connected...
Sequencing results returned in a few days; costs similar to conventional testing A new study from Washington University School of Medicine shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for blood cancers, such as acute myeloid leukemia and myelodysplastic syndrome. (Photo: Getty Images) March 10, 2021 SHARE For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab test...